Colorectal Cancer Biomarkers in the Era of Personalized Medicine
The 5-year survival probability for patients with metastatic colorectal cancer has not drastically changed over the last several years, nor has the backbone chemotherapy in first-line disease. Nevertheless, newer targeted therapies and immunotherapies have been approved primarily in the refractory s...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-01-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | http://www.mdpi.com/2075-4426/9/1/3 |
| _version_ | 1797761558122594304 |
|---|---|
| author | Jai N. Patel Mei Ka Fong Megan Jagosky |
| author_facet | Jai N. Patel Mei Ka Fong Megan Jagosky |
| author_sort | Jai N. Patel |
| collection | DOAJ |
| description | The 5-year survival probability for patients with metastatic colorectal cancer has not drastically changed over the last several years, nor has the backbone chemotherapy in first-line disease. Nevertheless, newer targeted therapies and immunotherapies have been approved primarily in the refractory setting, which appears to benefit a small proportion of patients. Until recently, rat sarcoma (RAS) mutations remained the only genomic biomarker to assist with therapy selection in metastatic colorectal cancer. Next generation sequencing has unveiled many more potentially powerful predictive genomic markers of therapy response. Importantly, there are also clinical and physiologic predictive or prognostic biomarkers, such as tumor sidedness. Variations in germline pharmacogenomic biomarkers have demonstrated usefulness in determining response or risk of toxicity, which can be critical in defining dose intensity. This review outlines such biomarkers and summarizes their clinical implications on the treatment of colorectal cancer. It is critical that clinicians understand which biomarkers are clinically validated for use in practice and how to act on such test results. |
| first_indexed | 2024-03-12T19:14:44Z |
| format | Article |
| id | doaj.art-25d7d2fe3ddd46a6bb7d3bf66a5c1240 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-12T19:14:44Z |
| publishDate | 2019-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-25d7d2fe3ddd46a6bb7d3bf66a5c12402023-08-02T05:36:01ZengMDPI AGJournal of Personalized Medicine2075-44262019-01-0191310.3390/jpm9010003jpm9010003Colorectal Cancer Biomarkers in the Era of Personalized MedicineJai N. Patel0Mei Ka Fong1Megan Jagosky2Department of Cancer Pharmacology, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USADepartment of Pharmacy, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USADepartment of Solid Tumor Oncology, Levine Cancer Institute, Atrium Health, Charlotte, NC 28204, USAThe 5-year survival probability for patients with metastatic colorectal cancer has not drastically changed over the last several years, nor has the backbone chemotherapy in first-line disease. Nevertheless, newer targeted therapies and immunotherapies have been approved primarily in the refractory setting, which appears to benefit a small proportion of patients. Until recently, rat sarcoma (RAS) mutations remained the only genomic biomarker to assist with therapy selection in metastatic colorectal cancer. Next generation sequencing has unveiled many more potentially powerful predictive genomic markers of therapy response. Importantly, there are also clinical and physiologic predictive or prognostic biomarkers, such as tumor sidedness. Variations in germline pharmacogenomic biomarkers have demonstrated usefulness in determining response or risk of toxicity, which can be critical in defining dose intensity. This review outlines such biomarkers and summarizes their clinical implications on the treatment of colorectal cancer. It is critical that clinicians understand which biomarkers are clinically validated for use in practice and how to act on such test results.http://www.mdpi.com/2075-4426/9/1/3biomarkerprognosticpredictivesomaticgermlinepharmacogenomicspersonalized medicine |
| spellingShingle | Jai N. Patel Mei Ka Fong Megan Jagosky Colorectal Cancer Biomarkers in the Era of Personalized Medicine Journal of Personalized Medicine biomarker prognostic predictive somatic germline pharmacogenomics personalized medicine |
| title | Colorectal Cancer Biomarkers in the Era of Personalized Medicine |
| title_full | Colorectal Cancer Biomarkers in the Era of Personalized Medicine |
| title_fullStr | Colorectal Cancer Biomarkers in the Era of Personalized Medicine |
| title_full_unstemmed | Colorectal Cancer Biomarkers in the Era of Personalized Medicine |
| title_short | Colorectal Cancer Biomarkers in the Era of Personalized Medicine |
| title_sort | colorectal cancer biomarkers in the era of personalized medicine |
| topic | biomarker prognostic predictive somatic germline pharmacogenomics personalized medicine |
| url | http://www.mdpi.com/2075-4426/9/1/3 |
| work_keys_str_mv | AT jainpatel colorectalcancerbiomarkersintheeraofpersonalizedmedicine AT meikafong colorectalcancerbiomarkersintheeraofpersonalizedmedicine AT meganjagosky colorectalcancerbiomarkersintheeraofpersonalizedmedicine |